New pyridine‐based chalcones and pyrazolines with anticancer, antibacterial, and antiplasmodial activities

New pyridine‐based chalcones 4a–h and pyrazolines 5a–h (N‐acetyl), 6a–h (N‐phenyl), and 7a–h (N‐4‐chlorophenyl) were synthesized and evaluated by the National Cancer Institute (NCI) against 60 different human cancer cell lines. Pyrazolines 6a, 6c–h, and 7a–h satisfied the pre‐determined threshold inhibition criteria, obtaining that compounds 6c and 6f exhibited high antiproliferative activity, reaching submicromolar GI50 values from 0.38 to 0.45 μM, respectively. Moreover, compound 7g (4‐CH3) exhibited the highest cytostatic activity of these series against different cancer cell lines from leukemia, nonsmall cell lung, colon, ovarian, renal, and prostate cancer, with LC50 values ranging from 5.41 to 8.35 μM, showing better cytotoxic activity than doxorubicin. Furthermore, the compounds were tested for antibacterial and antiplasmodial activities. Chalcone 4c was the most active with minimal inhibitory concentration (MIC) = 2 μg/mL against methicillin‐resistant Staphylococcus aureus (MRSA), while the pyrazoline 6h showed a MIC = 8 μg/mL against Neisseria gonorrhoeae. For anti‐Plasmodium falciparum activity, the chalcones display higher activity with EC50 values ranging from 10.26 to 10.94 μg/mL. Docking studies were conducted against relevant proteins from P. falciparum, exhibiting the minimum binding energy with plasmepsin II. In vivo toxicity assay in Galleria mellonella suggests that most compounds are low or nontoxic. A series of pyrazolines bearing the pyridine moiety (5/6/7) were synthesized by cyclocondensation of the new chalcones 4a–g. The N‐arylpyrazolines exhibited significant anticancer activity against different cancer cell lines and the N‐acetylpyrazolines and chalcones showed better antiplasmodial and antibacterial activity.